OVERVIEW

Expert Guidance on New Advances in Renal Cell Carcinoma is organized by i3 Health.

Release Date: November 17, 2020
Expiration Date: November 16, 2021

Target Audience:
Oncologists, urologists, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with renal cell carcinoma (RCC).

Statement of Need:
Kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States (ACS, 2020). An estimated 73,750 new cases are reported annually and 14,830 people die of the disease. Renal cell carcinoma, which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Due to its often asymptomatic presentation, many patients have advanced disease at diagnosis, which is associated with poor outcomes. The 5-year survival rate for patients with regional RCC is only 70% and drops to a dismal 12% for those with distant metastases (ACS, 2020).

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Assess recent clinical trial findings on first-line and second-line treatment of advanced RCC
• Tailor evidenced-based therapeutic strategies to individual patients with advanced RCC

Faculty:
• Bradley McGregor, MD (Chairperson)
Clinical Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute

• Robert Motzer, MD
Jack and Dorothy Byrne Chair in Clinical Oncology
Memorial Sloan Kettering Cancer Center